152 related articles for article (PubMed ID: 15679830)
1. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe.
Wang J; Williams CM; Hegele RA
Clin Genet; 2005 Feb; 67(2):175-7. PubMed ID: 15679830
[TBL] [Abstract][Full Text] [Related]
2. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe.
Hegele RA; Guy J; Ban MR; Wang J
Lipids Health Dis; 2005 Aug; 4():16. PubMed ID: 16098225
[TBL] [Abstract][Full Text] [Related]
3. In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs.
Hawes BE; O'neill KA; Yao X; Crona JH; Davis HR; Graziano MP; Altmann SW
Mol Pharmacol; 2007 Jan; 71(1):19-29. PubMed ID: 17005902
[TBL] [Abstract][Full Text] [Related]
4. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.
Ge L; Wang J; Qi W; Miao HH; Cao J; Qu YX; Li BL; Song BL
Cell Metab; 2008 Jun; 7(6):508-19. PubMed ID: 18522832
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.
Zambrano T; Saavedra N; Lanas F; Caamaño J; Salazar LA
Mol Diagn Ther; 2015 Feb; 19(1):45-52. PubMed ID: 25589339
[TBL] [Abstract][Full Text] [Related]
6. The c.-133A > G polymorphism in NPC1L1 gene influences the efficacy of ezetimibe monotherapy on apolipoprotein A1 in hyperlipidemic patients.
Zsíros N; Bodor M; Varga V; Berta E; Balogh I; Seres I; Paragh G; Harangi M
Pharmazie; 2014 Jun; 69(6):424-9. PubMed ID: 24974575
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
8. NPC1L1: evolution from pharmacological target to physiological sterol transporter.
Huff MW; Pollex RL; Hegele RA
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2433-8. PubMed ID: 16973966
[TBL] [Abstract][Full Text] [Related]
9. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe.
Ziajka PE; Reis M; Kreul S; King H
Am J Cardiol; 2004 Mar; 93(6):779-80. PubMed ID: 15019893
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
11. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption.
Altmann SW; Davis HR; Zhu LJ; Yao X; Hoos LM; Tetzloff G; Iyer SP; Maguire M; Golovko A; Zeng M; Wang L; Murgolo N; Graziano MP
Science; 2004 Feb; 303(5661):1201-4. PubMed ID: 14976318
[TBL] [Abstract][Full Text] [Related]
12. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment.
Berthold HK; Laaksonen R; Lehtimäki T; Gylling H; Krone W; Gouni-Berthold I
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):262-7. PubMed ID: 18072016
[TBL] [Abstract][Full Text] [Related]
13. Niemann-pick C1-like 1 mediates alpha-tocopherol transport.
Narushima K; Takada T; Yamanashi Y; Suzuki H
Mol Pharmacol; 2008 Jul; 74(1):42-9. PubMed ID: 18403720
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
15. Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells.
Yamanashi Y; Takada T; Suzuki H
J Pharmacol Exp Ther; 2007 Feb; 320(2):559-64. PubMed ID: 17135346
[TBL] [Abstract][Full Text] [Related]
16. Gene polymorphism and frequencies of the NPC1L1 gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia.
Kashiwabara Y; Kobayashi Y; Koba S; Kohyama N; Ohbayashi M; Murayama JI; Hirano T; Kobayashi Y; Yamamoto T
J Clin Pharm Ther; 2014 Oct; 39(5):551-4. PubMed ID: 24861377
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe: cholesterol lowering and beyond.
Bays HE; Neff D; Tomassini JE; Tershakovec AM
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):447-70. PubMed ID: 18402536
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
Knopp RH; Tsunehara C; Retzlaff BM; Fish B; Nguyen H; Anderson S; Nguyen T
Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.
Chuang P; Langone AJ
Am J Ther; 2007; 14(5):438-41. PubMed ID: 17890931
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
Schweitzer M; Makhoul S; Paliouras M; Beitel LK; Gottlieb B; Trifiro M; Chowdhury SF; Zaman NM; Wang E; Davis H; Chalifour LE
Atherosclerosis; 2016 Mar; 246():78-86. PubMed ID: 26761771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
